Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of drug candidates to treat cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; DCPS which is in preclinical trial for the treatment of acute myeloid leukemia; VRK1, which is in preclinical development to treat solid tumors; VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; and NNMT for the treatment of solid tumors/chronic kidney diseases. It is also developing STK25, which is in preclinical trial to treat metabolic liver disease that can lead to inflammation and fibrosis; and TREX1, which is in preclinical trial for the treatment of solid tumors and immuno-oncology. The company has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases and evaluation of the STK25 program. The company was incorporated in 2009 and is headquartered in Huddinge, Sweden.
Frequently asked questions
What sector does Sprint Bioscience AB (SPRINT) operate in?
Sprint Bioscience AB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Sprint Bioscience AB (SPRINT) current stock price?
As of the latest data, Sprint Bioscience AB stock price is SEK 3.41, with a previous close of SEK 3.23. Sprint Bioscience AB gained SEK 0.18 in the last trading session, representing a 5.57% increase.
What is Sprint Bioscience AB (SPRINT) current market capitalization?
Sprint Bioscience AB market cap is approximately 359.81 million.
What is Sprint Bioscience AB (SPRINT) Earnings Per Share (EPS)?
The trailing EPS is SEK 0.94, and the forward EPS is SEK 0.50.
What is Sprint Bioscience AB (SPRINT) Price-to-Earnings (P/E) ratio?
Sprint Bioscience AB current P/E ratio is 3.63, with a forward P/E of 6.82.
What is Sprint Bioscience AB (SPRINT) EBITDA?
Sprint Bioscience AB EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -14.07 million.
Does Sprint Bioscience AB (SPRINT) pay dividends?
No. Sprint Bioscience AB does not pay a dividend.
What is Sprint Bioscience AB (SPRINT) beta (volatility) score?
Sprint Bioscience AB has a beta of -0.503, indicating lower volatility than the overall market.
